QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NYSEAMERICAN:CVM

CEL-SCI Stock Forecast, Price & News

$9.39
-0.88 (-8.57%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.34
▼
$10.41
50-Day Range
N/A
52-Week Range
$7.08
▼
$40.91
Volume
747,773 shs
Average Volume
1.20 million shs
Market Capitalization
$404.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.06
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.


CEL-SCI logo

About CEL-SCI

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Headlines

Top 10 deletions from the MSCI US Investable Market 2500 Index during semi-annual rejig - Seeking Alpha
November 12, 2021 |  seekingalpha.com
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility - Yahoo Finance
October 22, 2021 |  finance.yahoo.com
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility - Business Wire
October 22, 2021 |  businesswire.com
Cramer's lightning round: I prefer Intuit over Mogo - CNBC
October 18, 2021 |  cnbc.com
Here is What Hedge Funds Think About Quotient Limited (QTNT) - Yahoo Finance
October 4, 2021 |  finance.yahoo.com
Notable Wednesday Option Activity: SIX, CVM, COST
September 29, 2021 |  nasdaq.com
CEL-SCI Shares Spike To Session Highs; Up 7%
September 18, 2021 |  benzinga.com
Notable Tuesday Option Activity: SAM, AXON, CVM - Nasdaq
August 31, 2021 |  nasdaq.com
CVM: Primum Non Nocere - Yahoo Finance
August 25, 2021 |  finance.yahoo.com
CVM: Primum Non Nocere
August 25, 2021 |  finance.yahoo.com
CEL-SCI's Tough Road Ahead - Seeking Alpha
August 20, 2021 |  seekingalpha.com
Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge - Yahoo Finance Australia
August 17, 2021 |  finance.yahoo.com
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results - Business Wire
August 16, 2021 |  businesswire.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CVM
Previous Symbol
CUSIP
N/A
CIK
725363
Web
www.cel-sci.com
Phone
(703) 506-9460
Fax
703-506-9471
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$560 thousand
Price / Sales
721.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
18.41

Profitability

EPS (Most Recent Fiscal Year)
($0.88)
Net Income
$-30.25 million
Net Margins
N/A
Pretax Margin
-115,637.94%
Return on Equity
-90.10%
Return on Assets
-56.87%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
9.64
Quick Ratio
9.34

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
43,028,000
Free Float
37,606,000
Market Cap
$404.03 million
Optionable
Optionable

Company Calendar

Last Earnings
8/16/2021
Today
12/01/2021
Next Earnings (Estimated)
12/29/2021
Fiscal Year End
9/30/2022

MarketRank™

Overall MarketRank™

1.18 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

How has CEL-SCI's stock price been impacted by Coronavirus?

CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CVM stock has decreased by 3.6% and is now trading at $9.39.
View which stocks have been most impacted by COVID-19.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Wednesday, December 29th 2021.
View our earnings forecast for CEL-SCI.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) released its quarterly earnings results on Monday, August, 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.12.
View CEL-SCI's earnings history.

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

CEL-SCI shares reverse split before market open on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:
  • Geert R. Kersten, CEO, Chief Financial Officer, Treasurer & Director
  • Patricia B. Prichep, Secretary & Senior Vice President-Operations
  • Eyal Talor, Chief Scientific Officer
  • William Jones, Vice President-Quality Assurance
  • Daniel H. Zimmerman, Senior VP-Research & Cellular Immunology

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Molecular Templates (MTEM), Gilead Sciences (GILD), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA), VBI Vaccines (VBIV) and CymaBay Therapeutics (CBAY).

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.66%), Geode Capital Management LLC (1.58%), Citadel Advisors LLC (0.00%), Voloridge Investment Management LLC (1.27%), Jane Street Group LLC (0.00%) and UBS Group AG (0.54%). Company insiders that own CEL-SCI stock include Eyal Talor, Geert R Kersten, John Cipriano, Patricia B Prichep, Peter R Young and Robert Eugene Watson.
View institutional ownership trends for CEL-SCI.

Which major investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Commonwealth Equity Services LLC, Caption Management LLC, Citigroup Inc., Wolverine Trading LLC, XR Securities LLC, CSS LLC IL, and Schonfeld Strategic Advisors LLC. Company insiders that have sold CEL-SCI company stock in the last year include Eyal Talor, and John Cipriano.
View insider buying and selling activity for CEL-SCI or view top insider-selling stocks.

Which major investors are buying CEL-SCI stock?

CVM stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Voloridge Investment Management LLC, Two Sigma Investments LP, GSA Capital Partners LLP, Rafferty Asset Management LLC, Citadel Advisors LLC, Two Sigma Advisers LP, and Geode Capital Management LLC. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Patricia B Prichep, Peter R Young, and Robert Eugene Watson.
View insider buying and selling activity for CEL-SCI or or view top insider-buying stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $9.39.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $404.03 million and generates $560 thousand in revenue each year. The company earns $-30.25 million in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does CEL-SCI have?

CEL-SCI employs 2,020 workers across the globe.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

Where are CEL-SCI's headquarters?

CEL-SCI is headquartered at 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at (703) 506-9460, via email at [email protected], or via fax at 703-506-9471.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.